Millendo Therapeutics to Host Prader-Willi Syndrome (PWS) Breakfast Symposium on Thursday, November 14, 2019

Prominent PWS clinical expert along with company management will discuss disease epidemiology, current treatment landscape and livoletide as a potential new therapy for PWS patients –

Live webcast to begin at 8:30 a.m. EST –

ANN ARBOR, Mich.--()--Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced today that it will host a PWS Breakfast Symposium on Thursday, November 14, 2019 from 8:30 a.m. to 10:30 a.m. EST. The event will feature a clinical and scientific presentation by Shawn E. McCandless, M.D., Professor and Head of Section, Genetics and Metabolism - Department of Pediatrics, University of Colorado School of Medicine and Children’s Hospital of Colorado. The Symposium will also include presentations from company management on the current treatment landscape for PWS, the status of Millendo’s development program and the opportunity for livoletide in PWS.

A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.

About Livoletide
Livoletide is an unacylated ghrelin analogue in late-stage clinical development for the treatment of Prader-Willi syndrome (PWS), a rare genetic disease characterized by hyperphagia, a chronic unrelenting hunger, that leads to obesity, metabolic dysfunction, reduced quality of life and early mortality. In March 2019, the company initiated a pivotal Phase 2b/3 clinical study of livoletide in patients with PWS. In a previous randomized, double-blind, placebo-controlled Phase 2 clinical trial in 47 patients with PWS, administration of livoletide once daily was associated with a clinically meaningful improvement in hyperphagia, as well as a reduction in appetite. Millendo has received both Orphan Drug Designation and Fast Track Designation for livoletide for the treatment of PWS from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency (EMA). For more information about Millendo’s pivotal study of livoletide (ZEPHYR) please visit www.clinicaltrials.gov (NCT03790865) or the Patients and Families portion of our website.

About Millendo Therapeutics, Inc.
Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit www.millendo.com.

Contacts

Millendo Investor Contact:
Stephanie Ascher
Stern Investor Relations
212-362-1200
stephanie.ascher@sternir.com

Millendo Media Contact:
Julie Bane
MacDougall
617-821-1089
jbane@macbiocom.com

Release Summary

Millendo to Host Prader-Willi Syndrome (PWS) Breakfast Symposium on Thursday, November 14, 2019 in New York City.

Contacts

Millendo Investor Contact:
Stephanie Ascher
Stern Investor Relations
212-362-1200
stephanie.ascher@sternir.com

Millendo Media Contact:
Julie Bane
MacDougall
617-821-1089
jbane@macbiocom.com